Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1

Size: px
Start display at page:

Download "Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1"

Transcription

1 Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1 ASAHI KASEI CHEMICALS CORPORATION CEOLUS R&D DEPARTMENT 1

2 CONTENTS General Characteristics of SWELSTAR TM MX-1 Special Properties of SWELSTAR TM MX-1 Application Fields of SWELSTAR TM MX-1 Mechanism of Dissolution Control by SWELSTAR TM MX-1 Conclusions 2

3 General Characteristics of SWELSTAR TM MX-1 Developed by Asahi Kasei Chemicals and Sanwa Cornstarch. Produced by physical modification of potato starch. Performs as matrix agent to control sustained drug release. Applicable for CR of drugs with various water solubilities. Dissolution controllable tablets in different media. Conformable to USP/NF, EP and JPE [Pregelatinized Starch]. 3

4 Special Properties of SWELSTAR TM MX-1 Water soluble and insoluble elements - Resistant to alpha-amylase High swelling ability by rapid hydration - Gel matrix structure - Independent of ionic strength in test media Strong gel matrix structure having resistance to erosion - Resistant to digestive tract motions Controllable gel strength with addition of water soluble material - Dissolution control - Zero-order release profile Low reactivity - High storage stability 4

5 Powder Properties of SWELSTAR TM MX-1 Particle morphology a) Dry state (SEM) b) Wet state (OM *1 ) Typical properties of MX-1 Bulky density [g/cm 3.27 ] Repose angle [ ] 36 * 1 Optical microscope Av. particle diameter [μm] Water holding capacity [%] Swelling volume [cm 3 /g] Water soluble content [%] Viscosity [mpa s] 2% solution at 25 ºC MX-1 consists of water soluble and insoluble substances. The insoluble part keeps the raw starch-like crystalline structure, contributing to its resistance to alpha-amylase. MX-1 forms gel matrix structure after swelling by rapid hydration. 5

6 Application Fields of SWELSTAR TM MX-1 Controlled release gel-matrix tablets Dissolution control of direct compression tablets - various drugs with different water solubilities - various media with different ph - different rotation speeds - storage stability of the drug release profile 6

7 Dissolution Control of Direct Compression Tablets Purpose of this study Generally, dissolution profile of direct compression (DC) tablets is faster than that of wet-granulation (WG) tablets. Therefore, it is not easy to adjust the dissolution profile of DC tablets to that of WG tablets in various test media required by the guideline for the bioequivalence tests of generic drugs. It was investigated whether it is possible to adjust the dissolution profile of DC tablets in different test media by using a small amount of MX-1 to the original dissolution profile of WG tablets. 7

8 Benefits of DC Method WG method Powder Granulation and drying granule Tableting Tablet DC method Powder Tableting Tablet DC method has no granulation and drying process, therefore it can give an effective cost reduction. 8

9 Experiment Procedure - Highly Water Soluble Drug - WG method SSA 1 MCC 2 Lactose 3 CS 4 HPC-L 5 7 wt% 1 wt% 15 wt% 5 wt%.75 wt%* (*Of total of above) 1 Sodium salicylic acid, Yoshitomi (Solubility in water: 125 mg/ml) 2 Microcrystalline cellulose, Ceolus PH-11, ASAHI KASEI 3 Pharmatose 2M, DMV-Fonterra 4 Corn starch, ST-C, Nippon Starch Chemical 5 Hydroxypropyl cellulose, Type L Granulation Drying High shear granulator VG-1 (Powrex Corporation), Load: 16g, Binder: 2g (6% HPC-L aq.), Impeller: 28rpm, Cross screw: 3rpm, Granulation time: 3min Fluidized bed granulator MP-1 (Powrex Corporation) Granule 141 μm Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) Evaluation Dissolution test Rotating paddle (5, 1 rpm) method with 9 ml medium: Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV) and Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) 9

10 Experiment Procedure - Highly Water Soluble Drug - SSA 1 MCC 2 Lactose 3 SiO2 4 DC-1 method 7 wt% 2 wt% 1 wt%.5 wt%* (*Of above total) SSA 1 MCC 2 Lactose 3 MX-1 or HPC-L 5 SiO2 4 DC-2 method 7 wt% 18-2 wt% -7 wt% 3-12 wt%.5 wt%* (*Of above total) 1 Sodium salicylic acid, Yoshitomi 2 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 3 Super-Tab TM, DMV-Fonterra 4 Silica, Aerosil 2, Nippon Aerosil 5 Hydroxypropyl cellulose, Type L Mixing for 3 min in PE bag Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) Evaluation Dissolution test Rotating paddle (5, 1 rpm) method with 9 ml medium, Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV) and Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) 1

11 Dissolution Profiles from WG Tablets and DC Tablets - Highly Water Soluble Drug - 1 ph Buffer 1.2 直打処方 DC-1 Tablets 1 DC-2 Method Tablets (MX-1) DC-1 Tablets 直打処方 溶出率 時間 湿打処方 WG Tablets 溶出率 時間 [min] DC-2 Tablets (HPC-L) 湿打処方 WG Tablets MX-1 3% MX-1 5% MX-1 6% DC-1 直打処方 Tablets Only 5% MX-1 demonstrates the same 6 sustained release profile of SSA from 4 DC tablets as the WG tablets, however HPC could not sustain release of SSA 2 even at 12%. 溶出率 時間 [min] WG Tablets 湿打処方 HPC-L 3% HPC-L 6% HPC-L 9% HPC-L 12% 11

12 The Influence of Different Test Media - Highly Water Soluble Drug - 1 ph Buffer Buffer ph 1.2 ph Buffer Buffer ph DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) DC-2 Tablets (12% HPC-L) DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) DC-2 Tablets (12% HPC-L) Water DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) DC-2 Tablets (12% HPC-L) MX-1 could adjust the dissolution profile of DC tablets in different test media to that of WG tablets

13 The Influence of Different Rotating Speeds - Highly Water Soluble Drug - DC-2 Tablets (5% MX-1) 溶出率 [%] WG Tablets 1rpm 5rpm ph Buffer 1.2 湿打処方 /1rpm 湿打処方 /5rpm rpm 5rpm 時間 [min] MX-1 shows the same dissolution profile as WG tablets at both conditions of 5 rpm and 1 rpm. 溶出率 [%] DC-2 Tablets (12% HPC-L) 1rpm 5rpm 湿打処方 /1rpm 湿打処方 /5rpm HPC-L 12% 5r HPC-L 12% 時間 [min] 13

14 Disintegration of Tablets - Highly Water Soluble Drug Water DC-1 Tablets WG Tablets DC-2 Tablets (5% MX-1) Disintegration Time [min] DC-2 Tablets (12% HPC-L) MX-1 could sustain release of SSA from DC tablets without delaying the disintegration time compared to WG tablets. 14

15 Experiment Procedure - Water Insoluble Drug - WG method Etz 1 Lactose 2 HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) 1 Ethenzamide, Yoshitomi (Solubility in water:.97 mg/ml) 2 Pharmatose 2M, DMV-Fonterra 3 Hydroxypropyl cellulose, Type L Granulation High shear granulator VG-1 (Powrex Corporation), Load: 15g, Water: 14g, Impeller: 28rpm, Cross screw: 3rpm, Granulation time: 3min Drying Fluidized bed granulator MP-1 (Powrex Corporation) Granule Tableting Evaluation COMIL (Powrex Corporation), Screen: 1.14mmφ, Spacer: 25mm, Frequency: 4Hz, - 141μm Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) -Dissolution test Rotating paddle (5 rpm) method with 9 ml medium, Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV), Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) and buffer ph 4. 15

16 Experiment Procedure - Water Insoluble Drug - DC-1 method DC-2 method Etz 1 Lactose 2 MCC 3 3 wt% 5 wt% 2 wt% Etz 1 Lactose 2 MCC 3 MX-1 or HPC-L 4 3 wt% wt% 2 wt% 6-15 wt% 1 Ethenzamide, Yoshitomi 2 Super-Tab TM, DMV-Fonterra 3 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 4 Hydroxypropyl cellulose, Type L Mixing for 3 min in PE bag Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face (Tablet hardness: about 6N) Evaluation -Dissolution test Rotating paddle (5 rpm) method with 9 ml medium, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV) 16

17 Dissolution Profiles from WG Tablets and DC Tablets - Water Insoluble Drug - 1 DC-1 Tablets ph buffer DC-2 Tablets Method (MX-1) WG Tablets DC-2 Tablets (HPC-L) MX 1:6% MX 1:8% Only 8% MX-1 demonstrates the same 6 sustained release profile of Etz from DC 4 tablets as the WG tablets, however HPC could not sustain the release of 2 Etz even at 15% HPC-L:1% HPC-L:15% 17

18 The Influence of Different Test Media on WG Tablets - Water Insoluble Drug WG (ph 1.2) WG (ph 6.8) WG (water) WG Tablets The dissolution profiles of WG tablets in ph buffer 6.8 and water show the biggest difference. Dissolution tests of DC tablets with either 5% MX-1 or 5% HPC were performed in ph buffer 6.8 and water. 18

19 The Influence of Different Test Media on DC Tablets - Water Insoluble Drug - WG tablet DC tablets with either 5% MX-1 or 5% HPC-L Etz 1 Lactose 2 HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) Etz 1 Lactose 4 MX-1 or HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) 1 Ethenzamide, Yoshitomi 2 Pharmatose 2M, DMV-Fonterra 3 Hydroxypropyl cellulose, Type L 4 Super-Tab TM, DMV-Fonterra WG Tablets DC Tablets (5% HPC-L) DC Tablets (5% MX-1) WG (ph 6.8) WG (water) DC with 5% HPC (ph 6.8) DC with 5% HPC (water) DC with 5% MX-1 (ph 6.8) DC with 5% MX-1 (water) Both WG tablets and DC tablets which contain 5% HPC showed faster dissolution in ph buffer 6.8 than in water. To the contrary, DC tablets which contain MX-1 showed the reverse action. Therefore HPC was used in order to enhance the dissolution in ph buffer 6.8 together with a main matrix agent, MX-1. 19

20 The Influence of Different Test Media on DC Tablets - Water Insoluble Drug - WG tablet DC tablets with 5% MX-1 and 5% HPC-L Etz 1 Lactose 2 HPC-L 3 3 wt% 7 wt% 5 wt%* (*Of total of above) Etz 1 Lactose 4 MCC 5 MX-1 HPC-L 3 3 wt% 4 wt% 2 wt% 5 wt% 5 wt% 1 Ethenzamide, Yoshitomi 2 Pharmatose 2M, DMV-Fonterra 3 Hydroxypropyl cellulose, Type L 4 Super-Tab TM, DMV-Fonterra 5 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 1 8 ph buffer Water 6 4 WG 6 4 WG 2 DC with 5% MX-1 + 5% HPC-L DC with 5% MX-1 + 5% HPC-L By using 5% MX-1 and 5% HPC, the dissolution profiles are closer to that of WG tablets, but not the same. It needs to be promoted in the later stage of the dissolution. 2

21 The Effect of PEG on Drug Release Profile - Water Insoluble Drug - DC tablets with 5% MX-1 and 5% HPC-L and 1% PEG Etz 1 Lactose 2 MCC 3 MX-1 HPC-L 4 PEG 5 3 wt% 3 wt% 2 wt% 5 wt% 5 wt% 1 wt% 1 Ethenzamide, Yoshitomi 2 Super-Tab TM, DMV-Fonterra 3 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 4 Hydroxypropyl cellulose, Type L 5 Polyethylene glycol, Macrogol 6, Sanyo 1 8 Buffer ph buffer ph Water %MX-1+5%HPC 5%MX-1+5%HPC+1%PEG %MX-1+5%HPC 5%MX-1+5%HPC+1%PEG By adding 1% PEG, the dissolution was restrained in the early stage and then it was promoted in the later stage. 21

22 Experiment Procedure - Water Insoluble Drug - DC-3 method Etz 1 Lactose 2 MCC 3 MX-1 HPC-L 4 PEG 5 3 wt% 3 or 33 wt% 2 wt% 5 wt% 5 wt% 7 or 1 wt% 1 Ethenzamide, Yoshitomi 2 Super-Tab TM, DMV-Fonterra 3 Microcrystalline cellulose, Ceolus UF-711, ASAHI KASEI 4 Hydroxypropyl cellulose, Type L 5 Polyethylene glycol, Macrogol 6, Sanyo Mixing for 3 min in PE bag.5% Mg-St 6 6 Magnesium Stearate, Taihei Chemical Industrial Co. Ltd. Tableting Rotary Press (Clean Press, Kikusui Seisakusho Ltd.), 12punches, 54rpm 18 mg, φ8 mm, round-face Evaluation -Dissolution test Rotating paddle (5 rpm) method with 9 ml media, Water, Artificial gastric buffer ph 1.2 (1st fluid in JP XIV), Artificial intestinal buffer ph 6.8 (2nd fluid in JP XIV) and Buffer ph 4. 22

23 Dissolution Profiles in Different Media - Water Insoluble Drug Water WG Tablets DC-1 Tablets DC-3 Tablets (7% PEG) DC-3 Tablets (1% PEG) It was possible to adjust the dissolution profile of DC tablets in different test media by using 5% MX-1 in combination with 5% HPC and 7-1% PEG to that of WG tablets. MX-1 acted as a sustained-release matrix and PEG was used to specifically control the dissolution profile. HPC was effective to enhance the dissolution in ph buffer 6.8, in which the WG tablet shows faster dissolution than in the other media Buffer ph Buffer ph Buffer ph Buffer ph Buffer ph Buffer ph

24 Disintegration of Tablets - Water Insoluble Drug Water DC-1 Tablets WG Tablets DC-3 Tablets (7% PEG) DC-3 Tablets (1% PEG) Disintegration Time [min] MX-1 could sustain release of Etz from DC tablets without delaying disintegration time compared to WG tablets. 24

25 Storage Stability of Drug Release under Accelerated Conditions - Water Insoluble Drug - Etz/Lactose/MCC/MX-1/HPC/PEG =3/33/2/5/5/7 Storage for 6 months under the condition of 4 C75%R.H. in sealed glass bottles 1 Water 1 ph Buffer Buffer ph 1.2 ph Buffer Buffer ph 6.8 Buffer ph Buffer ph 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 純水 4 75%RHオープン 時間 [min] 時間 [min] 時間 [min] 時間 [min] 8 WG Tablets-initial 湿打 -initial 直打 DC-3 -initial Tablets (7% 6 PEG)-initial 直打 -2week 直打 -1month 溶出率 [%] DC-3 Tablets (7% PEG)-2 weeks 4 DC-3 Tablets (7% PEG)-1 month 直打 DC-3-3month Tablets (7% 2 PEG)-3 months DC-3 Tablets (7% PEG)-6 months 直打 -6month 時間 [min] The release profiles of Etz from DC-3 tablets with 7% PEG hardly changed under accelerated conditions for 6 months. 25

26 Storage Stability of Drug Release under Accelerated Conditions - Water Insoluble Drug - Etz/Lactose/MCC/MX-1/HPC/PEG =3/3/2/5/5/1 Storage for 6 months under the condition of 4 C75%R.H. in sealed glass bottles 1 Water 1 ph Buffer Buffer ph 1.2 ph Buffer Buffer ph 6.8 ph Buffer Buffer ph 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 6 4 溶出率 [%] 純水 4 75%RH オープン 時間 [min] 1 時間 [min] 時間 [min] 時間 [min] 湿打 -initial 直打 -initial 直打 -2week 直打 -1month 直打 -3month 直打 -6month 溶出率 [%] 8 WG Tablets-initial DC-3 Tablets (7% PEG)-initial 6 DC-3 Tablets (7% PEG)-2 weeks 4 DC-3 Tablets (7% PEG)-1 month DC-3 Tablets (7% PEG)-3 months 2 DC-3 Tablets (7% PEG)-6 months 時間 [min] The release profiles of Etz from DC-3 tablets with 1% PEG hardly changed under accelerated conditions for 6 months. 26

27 How could SWELSTAR TM MX-1 Specifically Control the Dissolution Profile? In combination with PEG, MX-1 could restrain the dissolution of the DC tablets in the early stage and then promote dissolution in the later stage. The mechanism of the dissolution control by MX-1 and PEG was investigated. 27

28 Experiment Procedure - The Effect of PEG - APAP 1 MX-1 or HPMC 2 MCC 3 PEG 4 1 wt% 6 wt% 2-3 wt% -1 wt% 1 Acetaminophen, Yoshitomi (Solubility in water: 15.8 mg/ml) 2 Hydroxypropyl methylcellulose, Viscosity of 2% solution: 1mpa s 3 Microcrystalline cellulose, Ceolus KG-82, ASAHI 4 Polyethylene glycol, Macrogol 6, Sanyo Mixing for 3 min in PE bag Tableting Single press (MODEL-1321DW CREEP, AIKOH Engineering) 18 mg, φ8 mm, round-face, Compression force 6 kn Evaluation -Dissolution test Rotating basket (1 rpm) method with 9 ml medium Artificial intestinal buffer (2nd fluid in JP XIV), ph: 6.8, α-amylase 5 μg/l -Tablet weight & water absorbing capacity (WAC) Tablet being removed during dissolution test WAC= (TW wet TW dry ) / TW dry 1 TW wet : Tablet weight in wet state TW dry : Tablet weight after drying 28

29 Dissolution Profiles of Matrix Tablets - The Effect of PEG - 1 6% MX-1 6% HPMC 1 % Dissolution 8 Dissolution rate [%] PEG(%) Time (hr) % Dissolution Dissolution rate [%] PEG(%) Time (hr) In combination with 1% PEG, MX-1 restrained the dissolution of matrix tablets in the early stage and then promoted dissolution in the later stage, whereas HPMC showed no change of the dissolution with PEG. 29

30 Swelling and Erosion of Matrix Tablets during Drug Dissolution - The Effect of PEG - Tablet weight Wet weight in wet (mg) state [mg] Tablet weight in wet state swelling MX-1 PEG % MX-1 PEG1% HPMC PEG % HPMC PEG1% erosion Time(hr) [hr] Water Water absorbing capacity(%) [%] Water absorbing capacity MX-1 PEG % MX-1 PEG1% HPMC PEG % HPMC PEG1% Time Time(hr) [hr] Both MX-1 and HPMC swelled in the first 2 hours, and then eroded. Tablet weight in wet state showed that MX-1 experienced less erosion than HPMC especially without PEG. Addition of PEG increased water absorbing capacity and accelerated erosion for MX-1 after 5 hours. PEG did not affect swelling or erosion patterns of HPMC. 3

31 Assumed Mechanism: How could SWELSTAR TM MX-1 Specifically Control the Dissolution Profile with PEG? 6% MX-1 Matrix Tablet 1st stage Hydration of MX-1 particles was promoted, then strong gel layer was formed. Drug diffusion was restrained effectively. 2nd stage Excess water absorption decreases gel strength. Diffusion of drugs and erosion of gel layer were promoted remarkably. Water penetration was promoted by adding PEG Dissolution % Dissolution rate [%] st stage 2nd stage PEG: % PEG: 1 % 2 Time 4 [hr] Time (hr) 1 6% HPMC Hydration of HPMC particles was not largely affected by promoting water penetration, because hydration rate was very high originally. Dissolution % Dissolution rate [%] PEG: % PEG: 1 % Matrix Tablet Time (hr) Time [hr] 31

32 Assumed Mechanism: How could SWELSTAR TM MX-1 Sustain Release of Drug without Delaying Disintegration Time? 5% MX-1 Gel Layer Water Penetration Tablet Swelling Disintegration It is assumed that tablets containing 5% MX-1 disintegrate into fragments, and each fragment forms gel layer ( ) on its surface, which sustains the release of drug. 32

33 CONCLUSIONS MX-1 can sustain the release of drugs from DC tablets at low doses without delaying disintegration time, and adjust the dissolution profile to the original dissolution profile of WG tablets in combination with other excipients such as PEG. MX-1 is a sustained-release excipient which is applicable to varying conditions such as drugs with different water solubilities, various media with different ph and different rotation speeds. Tablets containing MX-1 show stable drug release profiles under accelerated conditions. MX-1 can perform as an effective and useful sustained-release excipient to control dissolution profiles of DC tablets. 33

34 Thank you for your attention! 34

DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ

DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ QbD Approach to Formulation of Hydrophilic Matrix Using Sample Kit of Hypromellose [Metolose SR] DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa,

More information

Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig

Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems D. Tewari, R. K. Lewis, W. W. Harcum and T Dürig PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-069-1 (Supersedes PTR-069) Page 1 of 8 Hydrodynamic Robustness of Hypromellose and Methylcellulose Based Modified Release Matrix Systems

More information

PHARMACEUTICAL TECHNOLOGY REPORT. Abstract Summary. Introduction. Experimental Methods. Consumer Specialties ashland.com

PHARMACEUTICAL TECHNOLOGY REPORT. Abstract Summary. Introduction. Experimental Methods. Consumer Specialties ashland.com PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-037-3 (Supersedes PTR-037-2) Page 1 of 7 Hydrodynamic Robustness of Hypromellose and Hydroxypropyl Cellulose Based Modified Release

More information

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications Hypromellose CONTENTS PAGE 2 Preface Matrix system Selection of METOLOSE grades Specifications Properties Powder Solution Application Related Patents 3 4-5 6 8 10 13 14 17 Please note: The information

More information

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation METHOCEL Premium Cellulose Ethers Application Data The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation INTRODUCTION Hydrophilic matrices

More information

Continuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016

Continuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016 Continuous Granulation Using a Twin-Screw Extruder Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016 What is a twin screw extruder and how to use it for continuous granulation? Dry feed:

More information

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN Int. J. Chem. Sci.: 10(4), 2012, 2199-2208 ISSN 0972-768X www.sadgurupublications.com DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN K. V. R. N. S. RAMESH *, B. HEMA KIRNAMAYI

More information

The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder

The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder The Particle Design of Cellulose and the Other Excipients for a Directly Compressible Filler-Binder Hiroto Miyamoto KNOWKATSU 1 Abstract Cellulose and saccharide are commonly used filler-binder. This summary

More information

Formulation and Evaluation

Formulation and Evaluation Chapter-5 Formulation and Evaluation 5.1 OBJECTIVE After successful taste masking and solubility enhancement of drugs in preliminary studies, by using Mannitol Solid Dispersion, next step includes the

More information

Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products

Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products 57. Starch Convention, Detmold, April 26-28, 2006 K.-J. Steffens Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products Starches, Pharmaceutical Applications _ Starches

More information

Critical material properties for the design of robust drug products : excipient functionality related characteristics

Critical material properties for the design of robust drug products : excipient functionality related characteristics Critical material properties for the design of robust drug products : excipient functionality related characteristics Dr Liz Meehan, Pharmaceutical Development, Macclesfield UK 1 Excipients Definition

More information

Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media

Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media Effect of Excipients on Dissolution: Case Studies with Bio-relevant/ Hydro-alcoholic Media Sandip B. Tiwari, Ph.D. Technical Director: South Asia Colorcon Asia Pvt. Ltd., Goa, India DISSO-INDIA 2013, May

More information

Biopharmaceutics Dosage form factors influencing bioavailability Lec:5

Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Biopharmaceutics Dosage form factors influencing bioavailability Lec:5 Ali Y Ali BSc Pharmacy MSc Industrial Pharmaceutical Sciences Dept. of Pharmaceutics School of Pharmacy University of Sulaimani 09/01/2019

More information

PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY

PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY Excipients are inactive ingredients used as carriers for the active ingredients in a pharmaceutical product. These may

More information

Table 1 Hydrophilicity of MC and HPMC Grades. Polymer Cloud Point ( C) Hydrophilicity MC HPMC Type 2910 HPMC Type

Table 1 Hydrophilicity of MC and HPMC Grades. Polymer Cloud Point ( C) Hydrophilicity MC HPMC Type 2910 HPMC Type PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-046-1 (Supersedes PTR-046) Page 1 of 6 Effect of Hypromellose and Methylcellulose Substitution Type, Molecular Weight and Drug Solubility

More information

FLORITER. New Technology for Innovative Formulation Design.

FLORITER. New Technology for Innovative Formulation Design. FLORITER New Technology for Innovative Formulation Design www.tomitaph.co.jp FLORITE Dramatically Change Your Formulation FLORITE is synthetic Calcium Silicate with exceptional liquid absorbency and excellent

More information

To study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets.

To study the effect that hydroxypropylcellulose (HPC) polymer molecular weight (MW) exerts on drug release rates and mechanism from matrix tablets. PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-029-1 (Supersedes PTR 029) Page 1 of 7 Hydroxypropylcellulose in Modified Release Matrix Systems: Polymer Molecular Weight Controls

More information

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods PHARMACEUTICAL TECHNOLOGY REPORT Consumer Specialties ashland.com PTR-8 Page 1 of 6 Are Cellulosic Controlled Release Technologies Vulnerable to Dose Dumping in Ethanolic Dissolution Media? Elanor Pinto,

More information

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD Int. J. Chem. Sci.: 6(3), 2008, 1270-1275 FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD K. P. R. CHOWDARY, P. TRIPURA SUNDARI and K. SURYA

More information

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations TECHNICAL INFORMATION 1426 RxCIPIENTS FM 1 A versatile excipient for orally disintegrating tablet (ODT) formulations Table of contents 1 Introduction 3 2 Mode of action and advantages of RxCIPIENTS FM

More information

Graphical Abstract. Final Step. Iwao et al. First Step Disintegrant. Second Step. Available surface area (St) using the data of dissolution study

Graphical Abstract. Final Step. Iwao et al. First Step Disintegrant. Second Step. Available surface area (St) using the data of dissolution study Graphical Abstract First Step Disintegrant Iwao et al. Second Step Available surface area (St) using the data of dissolution study t b F( t) 1 exp ( t / a) C /( C W / V ) df( t) dt S( t) V / k ln s s 0

More information

The unlocked synergy of DFE Pharma MCC

The unlocked synergy of DFE Pharma MCC The unlocked synergy of DFE Pharma MCC We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients for oral solid dose and dry powder inhalation formulations.

More information

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency Pharma & Food Solutions POLYOX TM Water Soluble Resins Combining Flexibility with Consistency POLYOX 9-13 POLYOX 9-13 POLYOX * are nonionic poly (ethylene oxide) polymers that meet all the specifications

More information

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants? Wettable Magnesium Stearate Presented By: Richard Pudlo P.E. Principal Chemical Engineer April 29 th, 2015 What Are Customers Looking for in Selecting Pharmaceutical Lubricants? Meet USP/.NF monograph

More information

CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION

CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION CHAPTER 8 HYDROGEL PLUG FORMULATION AND EVAUATION 8.1 Preparation of erodible tablet plug (Hydrogel Plug) Direct compression method was used to prepare the erodible tablet plug. The compositions of different

More information

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS Int. J. Chem. Sci.: 10(4), 2012, 1934-1942 ISSN 0972-768X www.sadgurupublications.com STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS K. VENUGOPAL * and K. P. R. CHOWDARY a Nirmala College

More information

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac Asian Journal of Chemistry Vol. 22, No. 6 (2010), 4239-4244 A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac K.P.R. CHOWDARY*

More information

Formulation and Development of Sustained Release Tablets of Valsartan Sodium

Formulation and Development of Sustained Release Tablets of Valsartan Sodium INTERNATIONAL JOURNAL OF ADVANCES IN PHARMACY, BIOLOGY AND CHEMISTRY Research Article Formulation and Development of Sustained Release Tablets of Valsartan Sodium G. Sandeep * and A. Navya Department of

More information

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies VIVAPHARM PVP/VA Copovidone, Ph.Eur. USP/NF, JPE, E 1208, FCC The Ultimate Tablet Binder for All Processing Technologies Direct Compression Dry Granulation Hot Melt Extrusion Wet Granulation VIVAPHARM

More information

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process Direct With the right ingredients it s a simple, cost-effective manufacturing process TM Trademark of The Dow Chemical Company ( Dow ) or an affiliated company of Dow Speed and savings sounds good to us

More information

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS International Journal of PharmTech Research CODEN( USA): IJPRIF ISSN : 0974-4304 Vol.1, No.3, pp 634-638, July-Sept 2009 FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS K. Reeta Vijaya

More information

STARCH Application Data

STARCH Application Data STARCH 1500 Application Data Partially Pregelatinized Maize Starch Starch 1500, Partially Pregelatinized Maize Starch, Used as a Binder Disintegrant in High Shear Wet Granulation Comparison to Povidone

More information

SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING

SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING Dr. Dieter Lubda MilliporeSigma is a business of Merck KGaA, Darmstadt, Germany Agenda: Sustained release

More information

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS

7. SUMMARY, CONCLUSION AND RECOMMENDATIONS 211 7. SUMMARY, CONCLUSION AND RECOMMENDATIONS Drug absorption from the gastro intestinal tract can be limited by various factors with the most common one being poor aqueous solubility and poor permeability

More information

Technical brochure StarLac

Technical brochure StarLac T R TABLETING AC DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is

More information

Office europeen des brevets. Publication number: Applicant: Chugai Seiyaku Kabushiki Kaisha 5-1, 5-chome, Ukima Kita-ku Tokyo(JP)

Office europeen des brevets. Publication number: Applicant: Chugai Seiyaku Kabushiki Kaisha 5-1, 5-chome, Ukima Kita-ku Tokyo(JP) J Europaisches Patentamt European Patent Office Publication number: 0 2 932 Office europeen des brevets A2 EUROPEAN PATENT APPLICATION Application number: 87100549.2 Date of filing: 16.01.87 int. Ci.

More information

Formulation and evaluation of oro-dispersible tablets of lafutidine

Formulation and evaluation of oro-dispersible tablets of lafutidine Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (5):226-235 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4

More information

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant EXCIPIENTS STARCH 1500 Proven and Trusted Excipient for Performance and Versatility Effective and economical disintegrant Excellent stability for moisture sensitive drugs Manufactured exclusively for the

More information

The binding performance of DFE Pharma Starch

The binding performance of DFE Pharma Starch The binding performance of DFE Pharma Starch MCC Starch Lactose Inhalation Superdisintegrants We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients

More information

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical Excipient Quality & Trouble Shooting By Seema Trivedi GM, Technical Back Ground The Society for Pharmaceutical Dissolution Science (SPDS) had held its 6th Annual International Convention Disso India -

More information

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012 STUDIES ON EFFECT OF SUPERDISINTEGRANTS ON ETORICOXIB TABLET FORMULATIONS Chowdary K. P. R 1, Venugopal. K *2 1 College of Pharmaceutical Sciences, Andhra University, Vishakapattanam. 2 * Nirmala college

More information

Studies of Rapidly Disintegrating Tablets in the Oral Cavity Using Co-ground Mixtures of Mannitol with Crospovidone

Studies of Rapidly Disintegrating Tablets in the Oral Cavity Using Co-ground Mixtures of Mannitol with Crospovidone February 2002 Chem. Pharm. Bull. 50(2) 193 198 (2002) 193 Studies of Rapidly Disintegrating Tablets in the Oral Cavity Using Co-ground Mixtures of Mannitol with Crospovidone Toshifusa SHU,* Hideshi SUZUKI,

More information

Re-compaction properties of lactose and microcrystalline cellulose

Re-compaction properties of lactose and microcrystalline cellulose Re-compaction properties of lactose and microcrystalline cellulose Individual excipients MCC Starch Lactose Inhalation Superdisintegrants SuperTab 21AN (anhydrous lactose) is the preferred form of lactose

More information

Formulation Study for Lansoprazole Fast-disintegrating Tablet. II. Effect of Triethyl Citrate on the Quality of the Products

Formulation Study for Lansoprazole Fast-disintegrating Tablet. II. Effect of Triethyl Citrate on the Quality of the Products September 2003 Chem. Pharm. Bull. 51(9) 1029 1035 (2003) 1029 Formulation Study for Lansoprazole Fast-disintegrating Tablet. II. Effect of Triethyl Citrate on the Quality of the Products Toshihiro SHIMIZU,*

More information

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients LubriTose Mannitol Michael Crowley, Director of R&D, Excipients Introduction Michael Crowley Director of R&D Excipients 158 St. Highway 320 Norwich, NY 13815 PH 315-802-5970 Michael.Crowley@Kerry.com 2

More information

Investigation of physicochemical drug properties to prepare fine globular. granules composed of only drug substance in fluidized bed rotor granulation

Investigation of physicochemical drug properties to prepare fine globular. granules composed of only drug substance in fluidized bed rotor granulation Mise R. et al., Page 1 1 2 Chem. Pharm. Bull. Note 3 4 5 Investigation of physicochemical drug properties to prepare fine globular granules composed of only drug substance in fluidized bed rotor granulation

More information

Technical brochure CombiLac

Technical brochure CombiLac OM I AC TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture is

More information

RESEARCH ARTICLE. Khemchand Gupta, S.B. Roy, Indrajeet Singhvi

RESEARCH ARTICLE. Khemchand Gupta, S.B. Roy, Indrajeet Singhvi RESEARCH ARTICLE ISSN: 2348-8948 Vol: 3; Issue: 6 PREFORMULATION STUDY IN THE DEVELOPMENT OF A TABLET FORMULATION FOR THE TREATMENT OF ULCERATIVE COLITIS Khemchand Gupta, S.B. Roy, Indrajeet Singhvi Pacific

More information

Int. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN:

Int. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN: International Research Journal of Pharmaceutical and Applied Sciences (IRJPAS) Available online at www.irjpas.com Int. Res J Pharm. App Sci., 2014; 4(1):47-51 Research Article FORMULATION AND EVALUATION

More information

METOLOSE: CONTENTS PAGE

METOLOSE: CONTENTS PAGE METOLOSE: CONTENTS PAGE 2 Preface What is Metolose Substitution types Specifications 1) Available grades & viscosity 2) Nomenclature 3) Packaging Characteristics of Metolose Properties of Metolose 1) Powder

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article FORMULATION DEVELOPMENT AND EVALUATION OF IMMEDIATE RELEASE BILAYER TABLETS OF TELMISERTAN AND HYDROCHLOROTHIAZIDE

More information

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium Available online on www.ijddt.com International Journal of Drug Delivery Technology 214; (3); 98-13 Research Article ISSN: 97 441 Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast

More information

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices METHOCEL Application Data Premium Cellulose Ethers The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices ABSTRACT SUMMARY This

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

More information

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/42

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/42 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 8 36 A1 (43) Date of publication: 14..09 Bulletin 09/42 (21) Application number: 084239.1 (1) Int Cl.: A61K 9/16 (06.01) A61K 9/ (06.01) A61K 31/4178 (06.01)

More information

Journal of Chemical and Pharmaceutical Research

Journal of Chemical and Pharmaceutical Research Available on line www.jocpr.com Journal of Chemical and Pharmaceutical Research ISSN No: 975-7384 CODEN(USA): JCPRC5 J. Chem. Pharm. Res., 211, 3(2):786-791 Development and optimization of colon targeted

More information

Formulation and evaluation of immediate release salbutamol sulphate

Formulation and evaluation of immediate release salbutamol sulphate 5 Formulation, optimization and evaluation of immediate release layer of salbutamol sulphate Salbutamol is moderately selective beta (2)-receptor agonist similar in structure to terbutaline and widely

More information

OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105

OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105 Digest Journal of Nanomaterials and Biostructures Vol. 9, No. 3, July September 2014, p. 1077-1084 OPTIMIZATION OF CONTROLLED RELEASE GASTRORETENTIVE BUOYANT TABLET WITH XANTHAN GUM AND POLYOX WSR 1105

More information

Research Article Formulation and Evaluation of Dual Component Tablets of Metoprolol tartrate

Research Article Formulation and Evaluation of Dual Component Tablets of Metoprolol tartrate Research Article Formulation and Evaluation of Dual Component Tablets of Metoprolol tartrate Rashmin N. Patel 1 * and Praful D. Bharadia 2 Department of Pharmaceutics, B. S. Patel Pharmacy College, Saffrony

More information

Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch

Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch Abstract K.P.R. Chowdary et al. / International Journal of Pharma Sciences and Research (IJPSR) Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch K.P.R. Chowdary*,

More information

Guidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples

Guidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples Guidance on Pharmaceutical Excipient Suitability Studies (PESS) with Chinese Pharmacopeia (Volume 4): Basics and Examples Professor Jiasheng Tu, Ph. D. France 2018/09 content 1 Introduction 2 PESS guidance

More information

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009 Co-Processed Excipients: Regulatory Challenges Carl Mroz Colorcon Limited June 2009 What is a Co-Processed excipient? Several types of excipient contain multiple components by design Use of processing

More information

TABLET DESIGN AND FORMULATION

TABLET DESIGN AND FORMULATION TABLET DESIGN AND FORMULATION PART 5 Industrial pharmacy 5th class 1st semester TABLET DESIGN AND FORMULATION Conventional oral tablets for ingestion usually contain the same classes of components in addition

More information

MODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY FLOATING APPROCHES

MODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY FLOATING APPROCHES Pooja et al Journal of Drug Delivery & Therapeutics; 213, 3(3), 37-41 37 Available online at http://jddtonline.info RESEARCH ARTICLE MODULATION OF GASTROINTESTINAL TRANSIT TIME OF SALBUTAMOL SULPHATE BY

More information

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS Int. J. Chem. Sci.: 8(1), 2010, 405-414 STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS V. L. NARASAIAH, T. KARTHIK KUMAR, D. SRINIVAS, K. SOWMYA, P. L. PRAVALLIKA and Sk. Md. MOBEEN

More information

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System Opadry Enteric Application Data Acrylic-Based Coating System Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System INTRODUCTION Acetylsalicylic acid (aspirin)

More information

Formulation and Evaluation of Gastroretentive Dosage form of Ciprofloxacin Hydrochloride.

Formulation and Evaluation of Gastroretentive Dosage form of Ciprofloxacin Hydrochloride. Available online on www.ijcpr.com International Journal of Current Pharmaceutical Review and Research, 3(4), 105-109 Research Article ISSN: 0976-822X Formulation and Evaluation of Gastroretentive Dosage

More information

SCIENTIFIC DISCUSSION. Efavirenz

SCIENTIFIC DISCUSSION. Efavirenz SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredient (API): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Rifampicin/Isoniazid 150mg/75mg filmcoated Tablets Svizera

More information

AnyCoat. From Nature, Beside you.

AnyCoat. From Nature, Beside you. AnyCoat From Nature, Beside you www.lotte-cellulose.com 04 AnyCoat is 05 Certificates of AnyCoat AnyCoat-C 06 General Characteristics 07 Specifications 08 Chemical Structure, Nomenclature 09 Functional

More information

PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE VEHICLE IN TABLET FORMULATIONS

PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE VEHICLE IN TABLET FORMULATIONS INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY Available online at www.ijrpc.com Research Article PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE

More information

Table 1. Coating Parameters

Table 1. Coating Parameters ACRYL-EZE Aqueous Acrylic Enteric System Application Data Performance Characteristics of Acryl-EZE, Aqueous Acrylic Enteric System Eudragit L1-55 is a copolymer of methacrylic acid and ethyl acrylate (1:1

More information

Granulation Aggregation

Granulation Aggregation Granulation Aggregation Wet granulation Solvent granulation (crust granules) Binder granulation (sticked granules) Granulation liquid Water Water + alcohol mixture Macromolecular colloidal solution i.e.:

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

More information

B. Jayakar et. al. FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLET OF CELECOXIB R. Margret Chandira, Shyam Sharma, Debjit Bhowmik, B.

B. Jayakar et. al. FORMULATION AND EVALUATION OF ORODISPERSIBLE TABLET OF CELECOXIB R. Margret Chandira, Shyam Sharma, Debjit Bhowmik, B. Page117 Online Available at www.thepharmaresearch.info THE PHARMA RESEARCH, A JOURNAL The Pharma Research (T. Ph. Res.), (2010), 4; 117-122. Published on- 15 Dec 2010 Copyright 2009 by Sudarshan Publication

More information

EFFECT OF SUPERDISINTEGRANTS ON RELEASE OF DOMPERIDONE FROM FAST DISSOLVING TABLETS

EFFECT OF SUPERDISINTEGRANTS ON RELEASE OF DOMPERIDONE FROM FAST DISSOLVING TABLETS ISSN: 22-7346 B. Sujatha et al. / JGTPS/ 5(3)-(2014) 1973 1978 (Research Article) Journal of Global Trends in Pharmaceutical Sciences Journal home page: www.jgtps.com EFFECT OF SUPERDISINTEGRANTS ON RELEASE

More information

WHOPAR. SCIENTIFIC DISCUSSION

WHOPAR. SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are included in parts 1

More information

3. Drug or plant or excipients profile

3. Drug or plant or excipients profile 3. Drug or plant or excipients profile 3. 1 Analysis of Reference Listed Drug (RLD) Product ABILIFY (aripiprazole) 3.1.1 Clinical The Reference Listed Drug (RLD) is Brand ABILIFY (aripiprazole) Tablets

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION This part reflects the scientific knowledge and the information about this product available at the time of prequalification. Thereafter, updates may have become necessary which are

More information

Easy, fast and reliable!

Easy, fast and reliable! Product Overview Easy, fast and reliable! Special easy-to-use preparations for film coating, sugar-coating, colouring and tabletting. s film coating products are one-step coating systems for pharmaceutical

More information

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100 IC OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE AC Technical brochure MEGGLE co-processed lactose grades for direct compression: General information Direct compression (DC) tablet manufacture

More information

Folic Acid in Human Nutrition

Folic Acid in Human Nutrition Folic Acid in Human Nutrition Folic acid is a water soluble B vitamin widely distributed in foods. Deficiencies lead to impaired cell division and altered protein synthesis. Newborn children of women receiving

More information

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Research Article

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY  ISSN Research Article INTERNATIONAL RESEARCH JOURNAL OF PHARMACY www.irjponline.com ISSN 2230 8407 Research Article FORMULATION AND EVALUATION OF BILAYERED FLOATING TABLETS OF METFORMIN HYDROCHLORIDE R.Margret Chandira*, P.Palanisamy,

More information

Content Uniformity of Direct Compression tablets

Content Uniformity of Direct Compression tablets Content Uniformity of Direct Compression tablets Contents 1 Summary 4 2 Introduction 4 3 The role of drug particle size 4 4 The role of mixing strategy 5 5 The role of excipients 5 6 Laboratory data 6

More information

1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small

1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small Lecture-5 1. Gastric Emptying Time Anatomically, a swallowed drug rapidly reaches the stomach. Eventually, the stomach empties its content in the small intestine. Because the duodenum has the greatest

More information

Design and In-vitro Evaluation of Silymarin Bilayer Tablets

Design and In-vitro Evaluation of Silymarin Bilayer Tablets CODEN (USA)-IJPRUR, e-issn: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Design and In-vitro Evaluation of Silymarin

More information

Karnataka Department of Pharmaceutical Technology, H.K.E. Society s College of Pharmacy, Gulbarga, Karnataka ABSTRACT KEYWORDS:

Karnataka Department of Pharmaceutical Technology, H.K.E. Society s College of Pharmacy, Gulbarga, Karnataka ABSTRACT KEYWORDS: 335 P a g e International Standard Serial Number (ISSN): 2319-8141 International Journal of Universal Pharmacy and Bio Sciences 4(6): November-December 2015 INTERNATIONAL JOURNAL OF UNIVERSAL PHARMACY

More information

LAB.2. Tablet Production Methods

LAB.2. Tablet Production Methods LAB.2 Tablet Production Methods Dry methods Direct compression Dry granulation Wet methods Wet granulation Regardless whether tablets are made by direct compression or granulation, the first step, milling

More information

Volker Bühler. Pharmaceutical Technology of BASF Excipients. Pharma Ingredients &Services. Welcome to more opportunities.

Volker Bühler. Pharmaceutical Technology of BASF Excipients. Pharma Ingredients &Services. Welcome to more opportunities. Volker Bühler Pharmaceutical Technology of BASF Excipients Pharma Ingredients &Services. Welcome to more opportunities. Volker Bühler Pharmaceutical Technology of BASF Excipients 3 rd revised edition June

More information

Primellose is an excellent choice as superdisintegrant in ODT applications

Primellose is an excellent choice as superdisintegrant in ODT applications Primellose is an excellent choice as superdisintegrant in ODT applications MCC Starch Lactose Inhalation Superdisintegrants Summary In orally disintegrating tablets, the excipients of choice in direct

More information

Innovations in Pharmaceuticals and Pharmacotherapy.

Innovations in Pharmaceuticals and Pharmacotherapy. Innovations in Pharmaceuticals and Pharmacotherapy www.innpharmacotherapy.com IPP eissn: 2321 323X Original Article Preformulation Studies for development of a generic capsule formulation of Celecoxib

More information

Formulation and Evaluation of Pulsatile Drug Delivery System of Rosuvastatin Calcium Using Different Swelling Polymers

Formulation and Evaluation of Pulsatile Drug Delivery System of Rosuvastatin Calcium Using Different Swelling Polymers ISSN: 2277-769 CODEN Code: PIHNBQ ZDB-Number: 266338-2 IC Journal No: 772 Vol. 1 No. 7 212 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION Formulation and Evaluation of Pulsatile Drug

More information

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/36

EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2009/36 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 09 81 A1 (43) Date of publication: 02.09.09 Bulletin 09/36 (1) Int Cl.: A61K 9/ (06.01) A61K 31/436 (06.01) (21) Application number: 0838007.3 (22) Date

More information

FABRICATION AND EVALUATION OF GLIMEPIRIDE CORDIA DICHOTOMA G.FORST FRUIT MUCILAGE SUSTAINED RELEASE MATRIX TABLETS

FABRICATION AND EVALUATION OF GLIMEPIRIDE CORDIA DICHOTOMA G.FORST FRUIT MUCILAGE SUSTAINED RELEASE MATRIX TABLETS Int. J. Chem. Sci.: 7(4), 2009, 2555-2560 FABRICATION AND EVALUATION OF GLIMEPIRIDE CORDIA DICHOTOMA G.FORST FRUIT MUCILAGE SUSTAINED RELEASE MATRIX TABLETS HINDUSTAN ABDUL AHAD *, B. PRADEEP KUMAR, C.

More information

Volume: 2: Issue-3: July-Sept ISSN FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL

Volume: 2: Issue-3: July-Sept ISSN FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL Volume: 2: Issue-3: July-Sept -2011 ISSN 0976-4550 FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL Ajaykumar Patil*, Ashish Pohane, Ramya Darbar, Sharanya Koutika, Alekhya

More information

Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M. Super-disintegrants and dissolution enhancers.

Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M. Super-disintegrants and dissolution enhancers. Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M Super-disintegrants and dissolution enhancers. 2 The Preface New: 4 dimensions of Kollidon CL standard, fine (CL-F), superfine (CL-SF) and micronized

More information

Adopting Technologies to Enhance Quality in Manufacturing

Adopting Technologies to Enhance Quality in Manufacturing Adopting Technologies to Enhance Quality in Manufacturing Sandip B. Tiwari, Ph.D. March 18, 2012 Current Status of Quality in Pharma Manufacturing Pharmaceutical manufacturing techniques lag behind those

More information

Compression and Mechanical Properties of Tablet Formulations

Compression and Mechanical Properties of Tablet Formulations Compression and Mechanical Properties of Tablet Formulations Containing Corn, Sweet, and Starches as Binders O.A. Odeku*, O.O. Awe, B. Popoola, M.A. Odeniyi, and O.A. Itiola The authors study the effects

More information

SCIENTIFIC DISCUSSION

SCIENTIFIC DISCUSSION SCIENTIFIC DISCUSSION Name of the Finished Pharmaceutical Product: Manufacturer of Prequalified Product: Active Pharmaceutical Ingredients (APIs): Pharmaco-therapeutic group (ATC Code): Therapeutic indication:

More information